Sequenom, Inc.
Genetic analysis products for biomedical research, molecular medicine and agricultural applications, including Sequenom’s MassARRAY® system
Sequenom was established in 1994 and currently has 115 employees.
Harry Stylli (CEO)
Paul W. Hawran (CSO)- effective 1. April 2007
John Sharp (VP, Finance)
Dereck Tatman (VP, Business Development)
Larry Myres (VP, Operations)
3595 John Hopkins Court
San Diego, CA 92121
USA
Phone: +1-858-202-9000
Fax: +1-858-202-9001
MassARRAY® Analyzer is a mass spectrometer for different genetic applications including the analysis of samples in real-time using matrix-assisted laser desorption / ionisation time-of-flight mass spectrometry.
MassARRAY® SNP Genotyping is able to analyze ten SNPs or hundreds of SNPs in thousands of samples or thousands of SNPs in just a few samples.
Related news
- Sequenom Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
- Leading U.S. Healthcare Providers Ordering Sequenom Center for Molecular Medicine's MaterniT21 LDT
- Sequenom Named to NASDAQ Global Select Market
- Sequenom Welcomes Suber Huang, M.D., to Ophthalmology Advisory Board
- Sequenom Center for Molecular Medicine Announces Launch of MaterniT21™ Noninvasive Prenatal Test for Down Syndrome
- Sequenom Center for Molecular Medicine Announces Launch of MaterniT21(TM) Noninvasive Prenatal Test for Down Syndrome
- Illumina Enters Collaborative Research Agreement with UNTHSC for Next-Generation Sequencing in Forensic DNA Analysis
- Sequenom Introduces iPLEX® ADME PGx Panel on MassARRAY® System
- Sequenom Announces European Licensing Agreement With LifeCodexx
- Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study
- Sequenom, Inc. Announces Date of First Quarter 2011 Financial Results and Conference Call
- Sequenom Reports Fourth Quarter and Full Year 2010 Financial Results
- Sequenom Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Sequenom Announces Date of Fourth Quarter 2010 Financial Results and Conference Call
- Sequenom CMM Announces Publication of 'Locked Assay' Study in American Journal of Obstetrics and Gynecology
- Professor Dennis Lo Trisomy 21 Clinical Validation Study Published in British Medical Journal
- Sequenom Announces Appointment of William Welch to Senior Vice President, Diagnostics
- Sequenom Announces Publication Acceptance of Manuscript From Trisomy 21 R&D Verification Study
- Sequenom CMM Commences Pivotal Clinical Validation Study for Its SensiGene Trisomy 21 Laboratory Developed Test
- Sequenom Announces $51.6 Million Private Placement
- Sequenom Introduces the MassARRAY Analyzer 4 System
- Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results
- Sequenom Announces Date of Full Year 2009 Financial Results and Conference Call
- Sequenom Announces Launch of SensiGene Fetal(XY) (Fetal Sex Determination) Test
- Sequenom Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostic Test
- Sequenom Announces Launch of SensiGene Fetal RHD Genotyping Test
- Sequenom Announces Settlement Agreement In Shareholder Class Action Lawsuit
- Sequenom Appoints Two New Board Members
- Sequenom Announces New Clinical Advisory Board Member
- SEQUENOM Announces Date of Third Quarter 2009 Financial Results and Conference Call
- Sequenom Announces Paul Maier to Become Interim Chief Financial Officer
- SEQUENOM Announces Completion of Independent Investigation
- SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test
- SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
- SEQUENOM Announces Launch of MassARRAY Compact 96 System
- University of Michigan Study Shows SEQUENOM's MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test
- SEQUENOM Reports First Quarter 2009 Financial Results
- SEQUENOM Announces Delay in Launch of SEQureDx Trisomy 21 Test
- SEQUENOM to Hold First Quarter 2009 Financial Results Conference Call on April 30
- SEQUENOM Announces Cost Cutting Initiative in Genetic Analysis Business
- Sequenom to Present at Two Investment Community Conferences in March
- Sequenom Adopts Share Purchase Rights Plan
- Sequenom Selects PDI to Provide Sales Team for Launch of Noninvasive Prenatal Screening Tests
- High-Throughput Genotyping of AML Patients for a Key Immune Receptor May Significantly Improve Treatment Outcome
- Sequenom Reports Fourth Quarter Financial Results
- Sequenom to Hold Fourth Quarter and Full Year 2008 Financial Results Conference Call on February 11
- Sequenom Announces Findings on Methylation Markers and RNA-SNP Markers as Presented at SMFM
- Sequenom to Hold Fourth Quarter and Full Year 2008 Financial Results Conference Call on February 11
- Sequenom Announces New Positive Data on Down Syndrome Detection and Unveils Breakthrough DNA Approach to Prenatal Diagnostics
- Webcast Alert: Sequenom: Defining the Future of Noninvasive Prenatal Diagnostics
- Sequenom Terminates Exchange Offer to Acquire EXACT Sciences
- Sequenom Names Allan T. Bombard, M.D., Chief Medical Officer
- Sequenom Expands Molecular Diagnostics Portfolio with Acquisition of SensiGen
- Sequenom: Defining the Future of Noninvasive Prenatal Diagnostics
- Sequenom Proposes to Acquire EXACT Sciences for $1.50 Per Share or Approximately $41 Million
- Sequenom to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 15
- Next-Generation Noninvasive Diagnostic Technology Shown to Accurately Detect Fetal Down Syndrome in First Trimester of Pregnancy
- New Noninvasive Prenatal Diagnostic Technology Allows Diagnosis of Inherited Diseases Such as Cystic Fibrosis Caused by Single Gene Mutations
- Sequenom Completes Acquisition of CLIA-Certified Laboratory
- Sequenom Announces Exclusive Licensing Agreement with Xenomics for Noninvasive Prenatal Diagnostics Using Transrenal DNA
- Sequenom Reports 2008 Third Quarter Financial Results
- Sequenom Announces Exclusive Licensing Agreement with Xenomics for Noninvasive Prenatal Diagnostics Using Transrenal DNA
- Sequenom Announces Additional, Positive Results for Down Syndrome Test at Analyst Briefing
- Sequenom Announces Acquisition of CLIA-Certified Laboratory and Partnerships with Spectrum Health and Van Andel Research Institute
- Sequenom Announces Exclusive Licensing Agreement with Genomic Nanosystems for Digital PCR Technologies and Methods Patents
- Sequenom to Webcast Analyst and Investor Briefing Presentation on September 23
- Sequenom Acquires Exclusive License to Digital PCR and Other Noninvasive Prenatal Diagnostic Intellectual Property
- Sequenom Certifies McGill University and Genome Quebec Innovation Centre as First Center of Excellence
- Sequenom to Present at Leerink Swann Emerging Products and Applications in Life Science Tools Conference
- Sequenom to Hold 2008 Second Quarter Financial Results Conference Call on July 30
- Sequenom Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares
- OHSU Cancer Institute to Use Sequenom's MassARRAY Technology for Cancer Research
- Sequenom Announces Results of Screening Studies for Down Syndrome and Updates Development of Noninvasive Prenatal Diagnostics at Analyst and Investor Briefing
- Johns Hopkins University Purchases Sequenom MassARRAY Platform
- Yale University Purchases Sequenom MassARRAY Platform
- Sequenom Announces Distribution Agreement with Invitrogen for South and Central America; Sells First MassARRAY System in Brazil
- Sequenom Updates 2008 Financial Guidance
- Sequenom Releases Cancer EpiPanel for High-Throughput Methylation Profiling of Cancer-Associated Genes
- Sequenom Reports 2007 Fourth Quarter and Full Year Financial Results
- Sequenom Announces Key Milestone in Development of Noninvasive Prenatal Down Syndrome Test
- Sequenom to Hold Fourth Quarter and Full Year 2007 Financial Results Conference Call on February 20
- Sequenom and NAFTNet to Conduct Fetal Rhesus D Study in Collaboration with Baylor College of Medicine
- MetaMorphix and Sequenom Agree to Build on Success
- Sequenom Announces New York State Approval of a Noninvasive Prenatal Test
- Sequenom to Sponsor Workshop Introducing Prenatal Diagnostics at AMP 2007 Annual Meeting
- Sequenom Names John A. Fazio to Board of Directors
- Sequenom Reports Third Quarter 2007 Financial Results
- Sequenom Announces $30 Million Private Placement
- Sequenom Announces Commercial Launch of New Assay Design and Validation Service and Online Customer Portal
- Sequenom to Develop Third-Generation Nanopore-Based Single Molecule Sequencing Technology
- Sequenom to Webcast Analyst and Investor Briefing Presentation on September 24
- Research Confirms Sequenom's EpiTYPER Application Provides Methylation Analysis Suitable for Comprehensive Gene Expression Profiling
- Research Confirms Sequenom's EpiTYPER Application Provides Methylation Analysis Suitable for Comprehensive DNA Methylation Profiling
- Sequenom Launches TYPER 4.0 Genotyping Software
- Sequenom to Webcast Analyst and Investor Briefing Presentation on September 24
- Sequenom to Webcast Analyst and Investor Briefing Presentation on September 24
- Sequenom to Present at ThinkEquity Partners 5th Annual Growth Conference
- Sequenom to Present at Leerink Swann & Company/MEDACorp Roundtable Conference
- Sequenom Reports Second Quarter 2007 Financial Results
- Sequenom to Hold Second Quarter 2007 Results Conference Call on August 6
- Richard A. Lerner, M.D. Named to Sequenom Board of Directors
- Lenetix Reports Submission of Clinical Data to New York State Authorities for the Commercial Launch of Non-Invasive Prenatal Rhesus D Incompatibility Test
- Sequenom and SensiGen Enter into Alliance to Develop and Commercialize Ultra-Sensitive Human Papillomavirus (HPV) Test and Other Advanced Proprietary Diagnostics
- Kathleen M. Wiltsey Named to Sequenom Board of Directors
- Sequenom to Provide Quantitative Gene Expression Services to the Immune Tolerance Network
- Sequenom to Present at Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference
- Sequenom Announces Positive Clinical Data and Performance for the Fetal Rhesus D Genotyping Assay
- Sequenom Reports First Quarter 2007 Financial Results
- Sequenom Announces Closing of $20 Million Registered Direct Offering
- Sequenom to Hold First Quarter 2007 Financial Results Conference Call on May 7
- Sequenom to Raise $20 Million in Registered Direct Offering Priced at a Premium to Market
- Use of Sequenom's MassARRAY System Leads to Significant Scientific Advances in Understanding Cancer, Diabetes and Drug-Resistant Malaria
- Sequenom Reports Fourth Quarter and Full Year 2006 Financial Result
- Sequenom to Hold Fourth Quarter and Full-Year 2006 Financial Results Conference Call on March 7
- Sequenom Names Financial Veteran Paul W. Hawran Chief Financial Officer
- Sequenom Expands Non-Invasive Prenatal Diagnostic Intellectual Property Portfolio
- MultiVu Video Feed: New Data Supports a Non-Invasive Approach to Routine Prenatal Genetic Testing
- Sequenom to Present at BIO CEO & Investor Conference 2007 on February 14
- Sequenom Names Steven Owings Vice President of Commercial Development, Prenatal Diagnostics
- Sequenom and Lenetix Enter Agreement to Develop and Commercialize Rhesus D Prenatal Diagnostic
- Sequenom to Present Scientific Poster at the Society of Maternal-Fetal Medicine Annual Meeting
- Sequenom's iPLEX Gold Assay Receives Positive Feedback From Leading Genomic Research Institutions
- Sequenom and Genus Enter Into Large Scale Livestock Genotyping Services Contract
- Sequenom Reports Multiple MassARRAY System Sales in South Korea
- Genome Institute of Singapore Upgrades Genetic Analysis Facility With Investment in Sequenom's MassARRAY Technology
- Sequenom and QIAGEN Enter Into Collaboration Targeting Prenatal Diagnostics
- Bovigen Announces USDA Process Verification Program Approval
- Study Published in 'Nature Genetics' by the University of California, San Diego Utilizes SEQUENOM's MassARRAY System in a Comprehensive Analysis of Microbial Evolution
- Sequenom Benefits From Favorable Ruling in European Patent Office Opposition Proceeding
- Sequenom Reports Third Quarter 2006 Financial Results
- Sequenom to Present at the Rodman & Renshaw 8th Annual Healthcare Conference on November 7
- Sequenom to Hold Third Quarter 2006 Financial Results Conference Call on November 2
- Sequenom Expands Non-Invasive Prenatal Diagnostic Testing Opportunity
- Sequenom Launches Next-Generation Genotyping Assay
- Bioneer Named Exclusive Distributor of Sequenom's MassARRAY Genetic Analysis Products in South Korea
- Paul W. Hawran Named to Sequenom Board of Directors
- Sequenom Names Michael Monko Senior Vice President of Sales and Marketing
- Sequenom to Hold 2006 Second Quarter Financial Results Conference Call on August 3
- Sequenom Selects Tata Consultancy Services to Develop Next Generation Framework for Life Science Software Applications
- Sequenom to Hold 2006 Second Quarter Financial Results Conference Call on August 3
- City of Hope to Use Sequenom's MassARRAY(R) System and Portfolio of Application Tools for Cancer Research
- Sequenom Granted Continued Listing on The Nasdaq National Market
- Sequenom Closes $33 Million Equity Financing
- Sequenom Hires Accomplished Diagnostics Executive Elizabeth (Betty) Dragon, Ph.D. to Lead Research and Development
- Sequenom Reports First Quarter 2006 Financial Results
- Sequenom Receives Notice of Additional Deficiency From Nasdaq
- Sequenom Invites You to Join Its Conference Call to Discuss First Quarter 2006 Financial Results and Corporate Highlights
- Nasdaq Grants Sequenom's Request for Exception to Comply With Listing Requirement
- Sequenom Provides Update on Audit Opinion